{"nctId":"NCT02674854","briefTitle":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2016-02"},"conditions":["Open-angle Glaucoma","Ocular Hypertension"],"count":750,"armGroups":[{"label":"PG324 Ophthalmic Solution 0.02%/0.005%","type":"EXPERIMENTAL","interventionNames":["Drug: PG324 Ophthalmic Solution 0.02%/0.005%"]},{"label":"Netarsudil (AR-13324) ophthalmic solution 0.02%","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Netarsudil (AR-13324) ophthalmic solution 0.02%"]},{"label":"Latanoprost ophthalmic solution 0.005%","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Latanoprost ophthalmic solution 0.005%"]}],"interventions":[{"name":"PG324 Ophthalmic Solution 0.02%/0.005%","otherNames":[]},{"name":"Netarsudil (AR-13324) ophthalmic solution 0.02%","otherNames":[]},{"name":"Latanoprost ophthalmic solution 0.005%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. 18 years of age or older (19 years of age or older in Canada)\n2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension(OHT) in both eyes\n3. Unmedicated intraocular pressure \\>20mmHg and \\<36mmHg in both eyes at 2 qualification visits\n4. Best corrected visual acuity (BCVA) equivalent to 20/200 Snellen or better\n5. Able to give informed consent and follow study instructions\n\nExclusion Criteria:\n\nOphthalmic:\n\n1. Clinically significant ocular disease\n2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles\n3. Unmedicated intraocular pressure ≥36mmHg in either eye or use of more than 2 ocular hypotensive medications within 30 days of screening\n4. Known hypersensitivity to any component of the formulation or latanoprost\n5. Previous glaucoma surgery or refractive surgery\n6. Ocular trauma within 6 months prior to screening\n7. Any ocular surgery or non-refractive laser treatment within 3 months prior to screening\n8. Recent or current ocular infection or inflammation in either eye\n9. Use of ocular medication in either eye of any kind within 30 days of screening and throughout of the study\n10. Mean central corneal thickness \\>620µm at screening in either eye\n11. Any abnormality preventing reliable applanation tonometry of either eye\n\n    Systemic:\n12. Clinically significant abnormalities in lab tests at screening\n13. Clinically significant systemic disease\n14. Participation in any investigational study within 60 days prior to screening\n15. Systemic medication that could have had a substantial effect on IOP within 30 days prior to screening, or anticipated to be used during the study\n16. Women of childbearing potential who were pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intraocular Pressure (IOP)","description":"Mean intraocular pressure(IOP) at 08:00, 10:00 and 16:00 hours, at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.69","spread":"3.422"},{"groupId":"OG001","value":"24.66","spread":"3.148"},{"groupId":"OG002","value":"24.75","spread":"3.240"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.33","spread":"3.399"},{"groupId":"OG001","value":"23.40","spread":"3.538"},{"groupId":"OG002","value":"23.23","spread":"3.339"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.37","spread":"3.492"},{"groupId":"OG001","value":"22.76","spread":"3.558"},{"groupId":"OG002","value":"22.59","spread":"3.451"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.06","spread":"3.370"},{"groupId":"OG001","value":"19.35","spread":"4.279"},{"groupId":"OG002","value":"18.10","spread":"3.375"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.31","spread":"3.272"},{"groupId":"OG001","value":"17.99","spread":"3.909"},{"groupId":"OG002","value":"17.61","spread":"3.264"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.16","spread":"3.032"},{"groupId":"OG001","value":"17.53","spread":"3.772"},{"groupId":"OG002","value":"17.08","spread":"3.283"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.43","spread":"3.717"},{"groupId":"OG001","value":"19.52","spread":"4.273"},{"groupId":"OG002","value":"17.93","spread":"3.586"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.54","spread":"3.533"},{"groupId":"OG001","value":"18.40","spread":"3.810"},{"groupId":"OG002","value":"17.35","spread":"3.224"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.45","spread":"3.525"},{"groupId":"OG001","value":"17.95","spread":"3.776"},{"groupId":"OG002","value":"17.09","spread":"3.271"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.45","spread":"3.572"},{"groupId":"OG001","value":"19.72","spread":"4.419"},{"groupId":"OG002","value":"17.98","spread":"3.400"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.58","spread":"3.307"},{"groupId":"OG001","value":"18.30","spread":"3.846"},{"groupId":"OG002","value":"17.48","spread":"3.366"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.52","spread":"3.210"},{"groupId":"OG001","value":"17.94","spread":"3.627"},{"groupId":"OG002","value":"17.14","spread":"3.044"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":244},"commonTop":["Conjunctival Hyperaemia","Instillation Site Pain","Cornea Verticillata","Conjunctival Haemorrhage","Instillation Site Discomfort"]}}}